BMJ Open by HOGAN, J. et al.
1Hogan J, et al. BMJ Open 2020;10:e037306. doi:10.1136/bmjopen-2020-037306
Open access 
Efficacy and safety of intravenous 
immunoglobulin with rituximab versus 
rituximab alone in childhood- onset 
steroid- dependent and frequently 
relapsing nephrotic syndrome: protocol 
for a multicentre randomised 
controlled trial
Julien Hogan   ,1,2 Aubriana Perez,2 Anne- Laure Sellier- Leclerc,3 Isabelle Vrillon,4 
Francoise Broux,5 Francois Nobili,6 Jerome Harambat,7 Lucie Bessenay,8 
V Audard,9 Camille Faudeux,10 Denis Morin,11 Christine Pietrement,12 
Stephanie Tellier,13 Djamal Djeddi,14 Philippe Eckart,15 Annie Lahoche,16 
G Roussey- Kesler,17 Tim Ulinski,18 Olivia Boyer,19 Emmanuelle Plaisier,20 
Sylvie Cloarec,21 Anne Jolivot,22 Vincent Guigonis,23 Sophie Guilmin- Crepon,1 
Veronique Baudouin,1 Claire Dossier,1 Georges Deschênes1,24
To cite: Hogan J, Perez A, 
Sellier- Leclerc A- L, et al.  
Efficacy and safety of 
intravenous immunoglobulin 
with rituximab versus 
rituximab alone in childhood- 
onset steroid- dependent 
and frequently relapsing 
nephrotic syndrome: protocol 
for a multicentre randomised 
controlled trial. BMJ Open 
2020;10:e037306. doi:10.1136/
bmjopen-2020-037306
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
037306).
Received 28 January 2020
Revised 22 July 2020
Accepted 23 July 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Julien Hogan;  
 julien. hogan@ aphp. fr
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Guidelines for the treatment of steroid- 
dependent nephrotic syndrome (SDNS) and frequently 
relapsing nephrotic syndrome (FRNS) are lacking. Given 
the substantial impact of SDNS/FRNS on quality of life, 
strategies aiming to provide long- term remission while 
minimising treatment side effects are needed. Several 
studies confirm that rituximab is effective in preventing 
early relapses in SDNS/FRNS; however, the long- term 
relapse rate remains high (~70% at 2 years). This trial will 
assess the association of intravenous immunoglobulins 
(IVIgs) to rituximab in patients with SDNS/FRNS and inform 
clinicians on whether IVIg’s immunomodulatory properties 
can alter the course of the disease and reduce the use of 
immunosuppressive drugs and their side effects.
Methods and analysis We conduct an open- label 
multicentre, randomised, parallel group in a 1:1 ratio, 
controlled, superiority trial to assess the safety and 
efficacy of a single infusion of rituximab followed by IVIg 
compared with rituximab alone in childhood- onset FRNS/
SDNS. The primary outcome is the occurrence of first 
relapse within 24 months. Patients are allocated to receive 
either rituximab alone (375 mg/m²) or rituximab followed 
by IVIg, which includes an initial Ig dose of 2 g/kg, followed 
by 1.5 g/kg injections once a month for the following 
5 months (maximum dose: 100 g).
Ethics and dissemination The study has been approved 
by the ethics committee (Comité de Protection des 
Personnes) of Ouest I and authorised by the French 
drug regulatory agency (Agence Nationale de Sécurité 
du Médicament et des Produits de Santé). Results 
of the primary study and the secondary aims will be 
disseminated through peer- reviewed publications.
Trial registration number NCT03560011.
INTRODUCTION
Background
Idiopathic nephrotic syndrome (INS) is the 
first glomerulopathy in children with an inci-
dence estimated between 2 and 3/100,000 
inhabitants and a high prevalence of 1/6250 
because of the extensive course of the disease. 
The response to steroid therapy (steroid- 
sensitive nephrotic syndrome vs steroid- 
resistant nephrotic syndrome (SRNS)) is 
of high prognostic significance. Cohort 
studies, including the French NEPHROVIR 
study, found that around 90% of the patients 
are steroid sensitive.1 2 However, 60% will 
Strengths and limitations of this study
 ► This study will be conducted as a national multi-
centre randomised controlled trial providing the first 
reliable data on the use of intravenous immunoglo-
bin in combination with rituximab in patients with 
idiopathic nephrotic syndrome.
 ► The lack of blinding of the patients and the physi-
cians is a limitation to the study design; however, 
the objectivity of the primary outcome reduces the 
risk of bias.
 ► Intravenous administration of the intervention ad-
dresses concerns of non- compliance.
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become steroid dependent or frequent relapsers with a 
major risk of morbidity related to the complications of 
the relapses (mostly infections due to immunoglobulin 
(Ig) loss and thrombosis) and to the side effects of the 
treatments used in those patients. The pathophysiology 
of INS is still incompletely understood. In 1974, Shaloub 
brought evidence for an immune origin of the disease.3 
Since then, standard immunosuppressive drugs such as 
calcineurin inhibitors or mycophenolate mofetil (MMF) 
demonstrated the ability to maintain remission while on 
treatment. Unfortunately, their effect is only suspensive 
with 75% of relapse after cyclosporine A (CsA) with-
drawal4 and over 90% of relapse after MMF withdrawal,5 
although maintenance of remission is needed to main-
tain normal renal function in the long run. Cyclophos-
phamide demonstrated a long- lasting effect in children 
with steroid- dependent nephrotic syndrome (SDNS) with 
a sustained remission rate of 42% at 2 years but its use 
is limited by its side effects.6 However, there is currently 
no consensus on the treatment of SDNS or frequently 
relapsing nephrotic syndrome (FRNS) and the Kidney 
Disease Improving Global Outcomes (KDIGO) guide-
lines only list potential steroid- sparing agents without 
giving indication which to prefer. Several strategies using 
low- dose steroid therapy (once every other day) and the 
immunosuppressive drugs mentioned previously have 
been proposed.7 8 However, they are associated with 
significant side effects such as diabetes, high blood pres-
sure, infections and renal fibrosis. Moreover, the long 
duration of the disease (median time 10 years) has been 
recently shown to significantly impact the quality of life 
of patients.9 Thus, treatment and strategies aiming to 
provide long- term remission while minimising treatment 
side- effects in patients with FRNS/SDNS need to be 
investigated.
In 2004, rituximab (RTX), a humanised anti- CD20 
antibody depleting B cells has been reported to induce 
sustained remission of the nephrotic syndrome in 
a patient treated for idiopathic thrombocytopenic 
purpura.10 Since then, many reports confirmed that 
RTX is able to induce long- lasting remission even after 
B cell recovery in patients with SDNS.11–13 This finding 
deeply modified our view on the pathophysiology of the 
disease with the involvement of B cells and not only T 
cells as previously described. This implication of B cells 
is further supported by the strong correlation between B 
cell recovery and INS relapse in patients relapsing after 
RTX therapy with a recent report underlying the role of 
memory B cells (CD19+/CD27+).14
Two recent randomised trials demonstrated an 
improvement of the relapse- free survival with RTX when 
compared with placebo or long- term steroid therapy.15 16 
Similar results have been found in a recently published 
French randomised controlled trial NEPHRUTIX since 
the relapse rates at 6 months was 10% in the RTX arm 
compared with 100% in the placebo arm.17 However, 
the remission rates after 2 years in patients treated with 
RTX is only 30%–40%. Strategies using repeated RTX 
injection with long B cell depletion duration greatly 
increase the relapse- free survival rate to over 60% but 
increase the risk of infection and persistent hypogamma-
globulinaemia.12 18 19
Intravenous Ig (IVIg), which is used for therapeutic 
purposes, is a polyspecific IgG preparation purified 
from plasma pools of several thousand healthy donors. 
IVIg preparations primarily contain human IgG mole-
cules, with small amounts of IgA and IgM. The distribu-
tion of IgG subclasses in IVIg is comparable to that of 
IgG in normal serum and the half- life of infused IVIg is 
approximately 3 weeks. IVIg was initially used as a substi-
tution for Igs that were lacking in patients with primary 
and secondary immune deficiencies. However, since the 
demonstration in 1981 that IVIg ameliorates immune 
thrombocytopenic purpura,20 IVIg is increasingly being 
used for the treatment of a wide range of autoimmune 
and systemic inflammatory diseases.21 In addition to 
antibody- mediated diseases, IVIg is also effective in 
several disorders caused by dysregulation of cellular 
immunity, such as Kawasaki disease, dermatomyositis, 
multiple sclerosis and graft versus host disease in recip-
ients of allogeneic bone marrow transplants.22 Clinically, 
the beneficial effects of IVIg extend beyond the half- life 
of infused IgG; therefore, its effects cannot be a result 
of a passive clearance or competition with pathogenic 
autoantibodies. Together, these observations evoke the 
possibility that IVIg therapy induces lasting changes in 
the cellular compartment of the immune system. Several 
studies demonstrated the ability of IVIg to modulate B 
cells immune response in vitro and in vivo through several 
mechanisms such as apoptosis promotion by modulating 
B- cell receptor (BCR) signalling after binding to CD22,23 
silencing programme induction of B cells and neutralisa-
tion of cytokines such as the B cell survival factor (BAFF) 
and a proliferation- inducing ligand.24 In vivo, IVIg 
therapy in women with recurrent spontaneous abortion is 
accompanied by a small decrease in the peripheral blood 
B cell numbers.25 Aside from their effects on B cells, IVIgs 
have been found to modulate T cell function especially 
by expanding and enhancing the functions of regulatory 
T cells26 27 and by decreasing T cell activation and prolif-
eration through multiple pathways, including interleukin 
2 production inhibition.28–30 Tha- In et al found that IVIgs 
were as effective as calcineurin inhibitors to inhibit T cells 
proliferation in vitro and also impact dendritic cells func-
tions.31 Many studies also report effects of IVIg on innate 
immune system.32
Thus, we hypothesised that the adjunction of IVIg to a 
single course of RTX may further modulate B cells func-
tion and allow a prolonged effect on INS without the 
need for long- lasting B cell depletion. Moreover, main-
taining a high IgG level may be beneficial in decreasing 
the risk of infection in those vulnerable patients. Treat-
ment modality was derived from the protocol commonly 
used to treat antibody- mediated rejection in renal trans-
plant recipients both in adults and in children.33 In a 
retrospective pilot study comparing 12 patients treated 
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with RTX and IVIg to 32 controls receiving one injection 
of RTX alone, we found a great improvement of relapse- 
free survival at 2 years from 40% in the RTX alone group 
to 70% in group receiving both RTX and IVIg with the 
difference remaining significant after adjustment for 
age, associated immunosuppressive treatments and B cell 
depletion duration (unpublished observations, J Hogan). 
The proposed clinical trial aims to establish evidence for 





Our primary objective is to assess the effect of a single 
infusion of RTX followed by Ig injections (once a month 
during 5 months) on the occurrence of the first relapse 
within 24 months following the initiation of treatment 
in patient with childhood onset FRNS/SDNS compared 
with a single infusion of RTX.
Secondary objectives
 ► To compare the time to first relapse.
 ► To compare the total number of relapse over the 24 
months of follow- up.
 ► To compare the cumulative dose of steroid over the 
24 months of follow- up.
 ► To compare the tolerance and safety of the two 
strategies.
Our hypothesis is that the adjunction of IVIg to RTX 
to treat patients with FRNS/SDNS will induce sustained 
remission of proteinuria even after oral treatment 
withdrawal and will improve relapse- free survival when 
compared with RTX used alone.
Study design
The trial will be an open- label multicentre, randomised, 
parallel group in a 1:1 ratio, controlled, superiority trial 
testing a single infusion of RTX followed by Ig injections 
(once a month during 5 months) compared with a single 
infusion of RTX, involving patients with childhood- 
onset FRNS/SDNS (figure 1). Because of the nature of 
the intervention, clinical investigators and patients will 
not be blinded to group assignment. Patients will be 
recruited from 22 tertiary nephrology care centres in 
France (table 1). Inclusions started in April 2019 and are 
expected to be completed in April 2021. The expected 
study completion date is April 2023.
Eligibility criteria
Study inclusion criteria comprises the following:
1. Childhood- onset nephrotic syndrome (first flare <18 
years old).
2. ≥2 years old at inclusion.
3. Steroid dependent: patient with at least 2 relapses 
confirmed during corticosteroids tapering or within 
2 weeks following steroids discontinuation, or patient 
with at least 2 relapses, including one under steroid- 
sparing agent (MMF, calcineurin inhibitors, cyclophos-
phamide and levamisole) or within 6 months of treat-
ment withdrawal.
4. Frequent relapsers: 2 or more relapses within 6 months 
after initial remission or 4 or more relapses within any 
12- month period with a relapse within 3 months prior 
to inclusion.
Figure 1 Flow diagram of the open- label randomised, multicentre, parallel- group, controlled, superiority trial, RITUXIVIG.
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5. In remission: protein- to- creatinine ratio ≤0.2 g/g 
(≤0.02 g/mmol).
Study exclusion criteria comprises the following:
1. Patients with SRNS.
2. Patients with genetic mutations known to be associat-
ed with nephrotic syndrome.
3. The presence of another active glomerular disease.
4. Patients previously treated with RTX.
5. Patients with no medical insurance.
6. Prior hepatitis B, hepatitis C or HIV infection or any 
severe and progressive infection.
7. Known congestive heart failure, left ventricular hy-
pertrophy or cardiomyopathy.
8. Pregnancy or breastfeeding (a pregnancy test is per-
formed before inclusion in the study in women of 
childbearing age and effective contraception will be 
given to these patients at inclusion. This contracep-
tion will be continued for 1 year after the last infusion 
of RTX).
9. Patients with hyperprolinaemia.
10. Known hypersensitivity to one of the study 
medications.
11. Scheduled and non- postponable injection of live at-
tenuated vaccine.
12. Adults under guardianship.
13. Patients with neutrophils <1.5×109/L and/or plate-
lets <75×109/L.
Outcomes
The primary outcome is the occurrence of the first relapse 
within 24 months following the initiation of treatment. 
Within this study, relapse shall be defined as a protein 
to creatinine ratio of 2 g/g of creatinine (0.2 g/mmol) or 
higher. No clinical manifestation is requested to define 
relapse. Second, we will monitor time to first relapse from 
the beginning of treatment, the total number of relapses 
occurring during the 24- month follow- up period, the 
cumulative dose of steroid taken during the 24- month 
follow- up, calculated as cumulative dose of corticosteroid 
for the enrolment episode plus the cumulative dose of 
corticosteroid for each relapse, the initiation of a new 
immunosuppressive therapy and the adverse events 
during the study period such as infectious complications, 
treatment tolerance, nausea and neutropenia.
Screening
When investigators observe a recurrence of INS in study 
candidate patients, they describe this clinical trial to the 
relevant subjects and obtain their written consent to partic-
ipate in the trial. After consent is obtained, screening 
tests are performed to verify eligibility as a subject. If the 
eligibility of the patient is confirmed after the screening 
tests, the patient is randomised. The randomisation must 
be performed within 3 months of the last relapse.
Randomisation
After obtaining written consent from all adults or from 
both parents of children (online supplemental material), 
randomisation will be performed using a web- based appli-
cation and a secured access (CleanWeb) in a 1:1 ratio to 
arm A: single infusion of RTX (375 mg/m²) or arm B: 
single infusion of RTX (375 mg/m²) followed by intrave-
nous polyvalent Ig once a month for 5 months according 
to a computer- generated list of randomly permuted 
blocks (mixed blocks). No stratification of the rando-
misation was planned. Randomisation and concealment 
will be achieved using a centralised, secure, computer- 
generated, interactive, web- response system accessible 
from each study centre. The randomisation time is the 
study time zero (M0). Blinding was not allowed given the 
nature of the intervention. However, this lack of blinding 
is partially counterbalanced by the objective nature of the 
primary outcome measure (biological criteria), and the 
final analysis will be blinded to allocation of groups.
Procedures
At day 0, all patients will undergo antibiotic prophylaxis 
with trimethoprim/sulfamethoxazole 800 mg three times 
per week until B cell reconstitution. All patients will 
receive a premedication with methylprednisolone and 
dexchlorpheniramine or hydroxyzine. Patients in both 
arms will then receive a single injection of RTX 375 mg/
m².
Table 1 List of the participating centres in France
City Hospital name
Amiens CHU d’Amiens
Besançon CHU de Besançon
Bordeaux CHU de Bordeaux
Caen CHU de Caen
Clermont Ferrand CHU Clermont Ferrand
Créteil CHU Henri Mondor
Lille CHU Jeanne de Flandre
Lyon Hôpital Mère Enfant
Montpellier CHU de Montpellier
Nancy CHU de Nancy
Nantes CHU de Nantes
Nice CHU Lenval
Paris CHU Armand Trousseau
Paris CHU Tenon
Paris CHU Necker
Paris CHU Robert Debré
Reims CHU de Reims
Rouen CHU de Rouen
Toulouse CHU de Toulouse
Tours CHU de Tours
Lyon Hôpital Edouard Herriot
Limoges Hôpital de la mère et de l’enfant
Total 22
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Patients randomised in arm B will receive two doses of 
IVIg (1 g/kg/day) over the course of two consecutive days 
beginning at month 1 (M1). From M2 to M5, patients in 
arm B will receive 0.75 g/kg/day on two consecutive days 
per month. Doses shall not exceed 100 g. Depending on 
respective centre practices and patient tolerance, IVIg 
will be administered in the centre outpatient clinic or 
conventional hospitalisation units.
Blood sampling
During the clinical trial period, investigators will perform 
observation, examination and blood sampling according 
to a predetermined schedule. On all days of investigational 
drug administration, blood samples are taken immedi-
ately prior to administration (table 2).
For all randomised patients, a monthly biological inves-
tigation in a local laboratory, including IgG, white blood 
cell and lymphocyte population count, and urine analysis, 
including protein- to- creatinine ratio, on a sample will be 
performed during 6 months or until B cell reconstitution, 
whichever is longer. Additionally, proteinuria will be eval-
uated once a week using a first- AM urinary dipstick until 
12 months after RTX injection and once every 2 weeks 
between 12 months and 24 months. If the results are posi-
tive, a confirmatory urine analysis will be carried out in 





1 2 3 4 5 6 9 12 18 24
Informed consent ○                     
History ○                     
Clinical examination ○                     
Blood sample for 
biobanking
○             ○
*
    ○*
Serology (HIV, HBV and 
HCV)
○                     
Haematological 
examination (total blood 
count and lymphocyte 
population count)
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Creatininemia ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
SGOT/SGPT and GGT ○                     
Serum electrolytes ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Protidemia ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
BUN ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Albuminaemia ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Proteinuria† ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Creatininuria ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
IgG serum level ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Randomisation ○                     
RTX infusion ○                     
Hospitalisation for IVIg‡   ○ ○ ○ ○ ○           
Follow- up visit 
(consultation)
      ○     ○ ○ ○ ○ ○
Relapse   ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Time to first relapse   ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Adverse event ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Pregnancy test*§ ○                     
*If relapse before M9 biobanking at relapse, if relapse after M9 biobanking at M9 and at relapse.
†Proteinuria is evaluated once a week using a urinary stick until 12 months after RTX injection and once every 2 weeks between 12 
months and 24 months.
‡If patient randomised in arm B.
§For patients at childbearing age.
BUN, Blood Urea Nitrogen; GGT, gamma glutamyl-transférase; HBV, Hepatitis B virus; HCV, Hepatitis C virus; IVIg, intravenous 
immunoglobulin; M0, month 0; M9, month 9; RTX, rituximab; SGOT, Serum Glutamo- Oxalacetique Transaminase; SGPT, serum 
glutamic- pyruvic transaminase.
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laboratory. All patients will also be included in a biorepos-
itory, including samples for DNA extraction and serum 
banking. The samples will be taken at M0, M9 (if no 
relapse before M9) and M24 (or at the time of relapse).
Follow- up visits will be carried out at M3, M6, M9, M12, 
M18 and M24 with an additional visit in case of relapse 
as routinely performed in clinical practice. All outcome 
measures (relapse, time of relapse, number of relapse 
and amount of corticosteroid taken) and adverse events 
will be assessed by the investigating physician during the 
follow- up visits.
Prohibited concomitant medications
Patients are instructed to stop all corticosteroids and 
immunosuppressive treatment (ie, MMF, levamisole, 
tacrolimus, CsA and prednisone) within 8 weeks of begin-
ning the trial. In case of corticosteroids treatment, weekly 
decrease of the dose will be implemented and stopped 
after 1 month. In case of treatment with steroid- sparing 
agent, discontinuation will occur after 8 weeks.
Adverse events
Adverse events are, according to the definitions, any unfa-
vourable or unintended event affecting patients on study. 
In cases of prolongation of hospitalisation, death or signif-
icant clinical sequelae, these events are defined as serious 
adverse events (SAEs), the occurrence of which the study 
sponsor (Assistance Publique – Hôpitaux de Paris, APHP) 
and the Data Safety Monitoring Board (DSMB) will be 
informed at short notice. During protocol treatment, all 
deaths, all SAEs that are life- threatening and any unex-
pected SAE must be reported to APHP using the SAE 
web form within 48 hours of the initial observation of the 
event.
Safety aspects of the study are closely assessed by the 
DSMB, which receives non- blinded data. Moreover, the 
first relapse of INS has been included as SAE to allow 
monitoring by the DSMB of any major discrepancy 
between the treatment groups.
Other adverse events monitored during the follow- up 
include infections requiring hospitalisation, infections 
not requiring hospitalisation, progressive multifocal 
leucoencephalopathy, neutropenia, acute kidney injury 
stage 3: increase in creatinine of ≥200% or estimated 
Glomerular Filtration Rate (eGFR) ≤35 mL/min/1.73 m2 
(if age <18 year) if patients with previously normal 
renal function, allergic reaction ≥grade 3 and infusion 
tolerance.
Data management
In the RITUXIVIG trial, the data are collected at each 
study visit. Data collection and data entry in the Elec-
tronic Case Report Form (eCRF) database are performed 
by the site investigators with the help of trained local 
research staff. A data management plan will be written 




The number of subjects required to compare the propor-
tion of patients with at least one relapse within 24 months 
between the two groups (RTX and IVIg vs RTX alone) 
was estimated. The proportion of patients with relapse 
at 24 months in the ‘RTX alone’ group is assumed to 
be approximately 60% based on previous reports.17 18 
Assuming a reduction of 30% in the RTX and IVIg group 
with a power of 80% and a two- sided type I error of 5%, 42 
patients per group are required throughout a 24 months’ 
recruitment period. Considering that the number of 
lost to follow- up will be relatively low in this population 
(follow- up of patients at 2 years is ~95%), size will be 
increased to 45 patients per group to provide an initial 
power of 80% on the intention to treat population.
Statistical analysis
The proportion of patients with at least one relapse within 
24 months (primary outcome) in the control group and 
the study group will be compared using a χ2 test. The 
Kaplan- Meier method will be used to study the time to 
first relapse and a log- rank test will be used to compare 
the time to first relapse between the study groups.
Comparison of the number of relapses, the number 
of adverse events and the cumulative doses of steroids 
over the study period will be performed using either a 
log- transform t- test for normally distributed variables 
or a Mann- Whitney U test for non- normally distributed 
variables (normality will be tested using a Kolmogorov- 
Smirnov test). All statistical tests will be two sided using a 
significance level of 5%.
Monitoring
Monitoring for quality and regulatory compliance will be 
performed in each centre by the study coordinator from 
the study coordinating centre. The frequency depends on 
inclusion rates, questions and pending issues from earlier 
audits: once or twice a year. In addition, quality control 
of the data is planned to detect missing and inconsis-
tent data. All missing data will be sought in the patients’ 
medical records. If missing data cannot be recovered by 
the study monitors, a multiple imputation procedure 
based on a ‘missing at random’ assumption using a fully 
conditional specification method will be considered.
Confidentiality and data handling
The data will be handled according to the French law. The 
eCRFs will be hosted by a service provided into a secure 
electronic system via a web navigator and protected by 
an individual password for each investigator and clinical 
research technician. Participant’s identifying informa-
tion will be replaced by a related sequence of characters 
to ensure confidentiality. The trial database file will be 
stored for 15 years. The sponsor is the owner of the data.
Patient and public involvement
Patients were not involved in the planning and produc-
tion of this study.
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Ethics and dissemination
The study was approved by the ethics committee (Comité 
de Protection des Personnes) of Ouest I on 24 April 2018 
and authorised by the French drug regulatory agency 
(Agence Nationale de Sécurité du Médicament et des 
Produits de Santé—EudraCT n°2017-000826-36) on 17 
May 2018. A manuscript with the results of the primary 
study and the secondary aims will be published in a peer- 
reviewed journal.
DISCUSSION
Childhood- onset steroid- dependent or frequently 
relapsing INS is a chronic disease with a long- lasting 
course and significant impact on patients’ quality of life. 
There are currently no clear guidelines to choose the best 
treatment for these patients, and the current treatment 
strategies are all associated with a high rate of relapse. 
Therefore, clinical trials testing new strategies of treat-
ment and assessing their long- term effects are needed.
The main goal of the RITUXIVIG trial is to demon-
strate the superiority of the association of RTX and IVIg 
compared with RTX alone. This trial has several strengths, 
including its multicentre design, the intravenous adminis-
tration of the drugs that alleviates concerns about compli-
ance and the choice of a long- term outcome (relapse- free 
survival at 2 years) compared with previous trials. Despite 
the trial being open- label, the risk of bias should be low, 
given the absence of non- compliance risk and the objec-
tive nature of the primary outcome.
This trial will provide the first assessment of the use of 
IVIg in patients with INS and inform clinicians on whether 
IVIg’s immunomodulatory properties can alter the course 
of the disease. Finally, this strategy may reduce the risk of 
infection associated with current strategies by reducing 
the amount of immunosuppressive drugs used and by the 
direct protective effect of IVIg against infections.
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